Citations

Clear

3314 citation(s) found for "Do, Alexander".

Energy‐integrating‐detector multi‐energy CT: Implementation and a phantom study
Ren, Liqiang , Allmendinger, Thomas , Halaweish, Ahmed F., Schmidt, Bernhard , Flohr, Thomas , Yu, Lifeng , McCollough, Cynthia H. , Yu, Lifeng

Mayo Clinic

Medical Physics | May 14, 2021 | Volume: 48 | Issue: 9 | Pages: 4857-4871

10.1002/mp.14943 | PMID 33988849 Get It

PurposeMulti‐energy computed tomography (MECT) has a great potential to enable many novel clinical applications such as simultaneous multi‐contrast imaging. The purpose of this study was to implement triple‐beam MECT on a traditional energy‐integrating‐detector (EID) CT platform (EID‐MECT).MethodsThis was accomplished by mounting a z‐axis split‐filter (0.05 mm Au, 0.6 mm Sn) on Tube A of a dual‐source EID CT scanner. With the two split x‐ray beams from Tube A and the third beam from Tube B, three beams with different x‐ray spectra can be simultaneously acquired. With Tube B operated at 70 or 80 kV and Tube A at 120 or 140 kV, four different triple‐beam configurations were calibrated for MECT measurements: 70/Au120/Sn120, 80/Au120/Sn120, 70/Au140/Sn140, and 80/Au140/Sn140 kV. Iodine (I), gadolinium (Gd), bismuth (Bi) samples, and their mixtures were prepared for 2 three‐material‐decomposition tasks and 1 four‐material‐decomposition task. For each task, samples were placed in a water phantom and scanned using each of the four triple‐beam configurations. For comparison, the same phantom was also scanned using three other dual‐energy CT (DECT) or MECT technologies: twin‐beam DECT (TB‐DECT), dual‐source DECT (DS‐DECT), and photon‐counting‐detector CT (PCD‐CT), all with optimal x‐ray spectrum settings and at equal volume CT dose index (CTDIvol). The phantom for four‐material decomposition (I/Gd/Bi/Water imaging) was scanned using the PCD‐CT only (140 kV with 25, 50, 75, and 90 keV). Image‐based material decomposition was performed to acquire material‐specific images, on which the mean basis material concentrations and noise levels were measured and compared across all triple‐beam configurations in EID‐MECT and various DECT/MECT systems.ResultsThe optimal triple‐beam configuration was task‐dependent with 70/Au120/Sn120, 70/Au140/Sn140, and 70/Au120/Sn120 kV for I/Gd/Water, I/Bi/Water, and I/Gd/Bi/Water material decomposition tasks, respectively. At equal radiation dose level, EID‐MECT provided comparable or better quantification accuracy in material‐specific images for all three material decomposition tasks, compared to EID‐based DECT and PCD‐CT systems. In terms of noise level comparison, EID‐MECT‐derived material‐specific images showed lower noise levels than TB‐DECT and DS‐DECT, but slightly higher than that from PCD‐CT in I/Gd/Water imaging. For I/Bi/Water imaging, EID‐MECT showed a comparable noise level to DS‐DECT, and a much lower noise level than TB‐DECT and PCD‐CT in all material‐specific images. For the four‐material decomposition task involving I/Gd/Bi/Water, the bismuth‐specific image derived from EID‐MECT was slightly noisier, but both iodine‐ and gadolinium‐specific images showed much lower noise levels in comparison to PCD‐CT.ConclusionsFor the first time, an EID‐based MECT system that can simultaneously acquire three x‐ray spectra measurements was implemented on a clinical scanner, which demonstrated comparable or better imaging performance than existing DECT and MECT systems.
Nanoprojectile Secondary Ion Mass Spectrometry for Analysis of Extracellular Vesicles
Verkhoturov, Dmitriy S., Crulhas, Bruno P. , Eller, Michael J. , Han, Yong Duk, Verkhoturov, Stanislav V. , Bisrat, Yordanos, Revzin, Alexander , Han, Yong D, Schweikert, Emile A , Eller, Michael J

Mayo Clinic

Analytical Chemistry | May 14, 2021 | Volume: 93 | Issue: 20 | Pages: 7481-7490

10.1021/acs.analchem.1c00689 | PMID 33988360 Get It

Gene-Environment Interactions Relevant to Estrogen and Risk of Breast Cancer: Can Gene-Environment Interactions Be Detected Only among Candidate SNPs from Genome-Wide Association Studies?
Park, JooYong , Choi, Ji‐Yeob , Chung, Seokang , Song, Nan , Park, Sue K. , Han, Wonshik , Noh, Dong‐Young , Ahn, Sei-Hyun, Lee, Jong Won, Kim, Mi Kyung , Jee, Sun Ha , Wen, Wanqing , Bolla, Manjeet K. , Wang, Qin , Michailidou, Kyriaki , Shah, Mitul , Conroy, Don, Harrington, Patricia, Mayes, Rebecca , Hall, Per , Patel, Alpa V. , Couch, Fergus J. , Sawyer, Elinor J. , Roylance, Rebecca , Bojesen, Stig E. , Flyger, Henrik, Lambrechts, Diether , Baten, Adinda , Matsuo, Keitaro , Ito, Hidemi , Guénel, Pascal , Keeman, Renske , Schmidt, Marjanka K. , Wu, Anna H. , Tseng, Chiu-Chen, Cox, Angela , Investigators, kConFab, Andrulis, Irene L. , Hopper, John L., Wu, Pei‐Ei , Shen, Chen‐Yang , Fasching, Peter A. , Ekici, Arif B. , Muir, Kenneth, Brenner, Hermann , Arndt, Volker , Jones, Michael E. , Swerdlow, Anthony J, Hoppe, Reiner , Ko, Yon-Dschun, Hartman, Mikael , Li, Jingmei , Mannermaa, Arto, Hartikainen, Jaana M. , Benítez, Javier, Haiman, Christopher A. , Dörk, Thilo , Bogdanova, Natalia , Teo, Soo‐Hwang , Taib, Nur Aishah Mohd , Fletcher, Olivia, Johnson, Nichola , Grip, Mervi, Winqvist, Robert , Nevanlinna, Heli , Lindblom, Annika , Wendt, Camilla, Kristensen, Vessela N. , Collaborators, NBCS, Tollenaar, Rob A.�E.�M. , Heemskerk‐Gerritsen, Bernadette A. M. , Bonanni, Bernardo , Hamann, Ute, Manoochehri, Mehdi, Martinez, Maria Elena, Easton, Douglas F., Yoo, Keun-Young, Lambrechts, Diether , Song, Nan , Park, Sue K , Kim, Mi Kyung , Dennis, Joe , Michailidou, Kyriaki , Hall, Per N , Matsuo, Keitaro , Ito, Hidemi , Keeman, Renske , Schmidt, Marjanka K , Fasching, Peter A , Brenner, Hermann , Arndt, Volker , Hartikainen, Jaana M , Dörk, Thilo , Bogdanova, Natalia V , Johnson, Nichola , Nevanlinna, H , Heemskerk-Gerritsen, Bernadette A M , Bonanni, Bernardo , Lambrechts, Diether , Teo, Soo H , Jones, Michael E , Lambrechts, Diether , Cox, Angela , Guénel, Pascal , Hartman, Mikael , Li, Jingmei , Ekici, Arif B , Bojesen, Stig E , Lindblom, Annika , Mohd Taib, Nur Aishah , Sawyer, Elinor J , Choi, Jaesung , Czene, Kamila , Teras, Lauren R. , Couch, Fergus J. , Olson, Janet E. , Truong, Thérèse , Cross, Simon S. , Investigators, kConFab, Southey, Melissa C. , Lophatananon, Artitaya , Ko, Yon‐Dschun, Mannermaa, Arto , González‐Neira, Anna , Fletcher, Olivia , Blomqvist, Carl , Wendt, Camilla, Collaborators, NBCS, Radice, Paolo , Manoochehri, Mehdi, Lacey, James V. , Dunning, Alison M. , Pharoah, Paul D.P. , Kang, Daehee

Mayo Clinic

Cancers | May 14, 2021 | Volume: 13 | Issue: 10 | Pages: 2370

10.3390/cancers13102370 | PMID 34069208 Get It

In this study we aim to examine gene–environment interactions (GxEs) between genes involved with estrogen metabolism and environmental factors related to estrogen exposure. GxE analyses were conducted with 1970 Korean breast cancer cases and 2052 controls in the case-control study, the Seoul Breast Cancer Study (SEBCS). A total of 11,555 SNPs from the 137 candidate genes were included in the GxE analyses with eight established environmental factors. A replication test was conducted by using an independent population from the Breast Cancer Association Consortium (BCAC), with 62,485 Europeans and 9047 Asians. The GxE tests were performed by using two-step methods in GxEScan software. Two interactions were found in the SEBCS. The first interaction was shown between rs13035764 of NCOA1 and age at menarche in the GE|2df model (p-2df = 1.2 × 10−3). The age at menarche before 14 years old was associated with the high risk of breast cancer, and the risk was higher when subjects had homozygous minor allele G. The second GxE was shown between rs851998 near ESR1 and height in the GE|2df model (p-2df = 1.1 × 10−4). Height taller than 160 cm was associated with a high risk of breast cancer, and the risk increased when the minor allele was added. The findings were not replicated in the BCAC. These results would suggest specificity in Koreans for breast cancer risk.
EGFR Inhibitors Plus Bevacizumab are Superior Than EGFR Inhibitors Alone as First-Line Setting in Advanced NSCLC With EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP)
Cardona, Andrés F. , Ordóñez‐Reyes, Camila , Ruíz-Patiño, Alejandro , García-Robledo, Juan Esteban , Barron, L. Zatarain, Recondo, Gonzalo , Rojas, Leonardo , Corrales, Luis , Martín, Claudio , Barrón, Feliciano , Sotelo, Carolina , Rodríguez, July, Ricaurte, Luisa , Ávila, Jenny , Mayorga, D., Archila, Pilar , Otero, Jorge, Bermúdez, Maritza , Gámez, Tatiana , Carranza, Hernán, Vargas, Carlos , Barron, Lucia Zatarain , Rolfo, Christian , Ávila, Jenny , Bermudez, Maritza , Gamez, Tatiana , Rosell, Rafael , Arrieta, Oscar , Cardona, Andrés F , Ordóñez-Reyes, Camila , Garcia-Robledo, Juan Esteban , Sotelo-Rodríguez, Carolina , Rojas, Leonardo , Zatarain-Barrón, Zyanya Lucía , Más, Luís , Rosell, Rafael , Arrieta, Óscar

Mayo Clinic

JCO Precision Oncology | May 13, 2021 | Volume: No volume available | Issue: 5 | Pages: 839-848

10.1200/po.20.00404 | PMID 34994616 Get It

PURPOSE BIM activation is essential for epidermal growth factor receptor ( EGFR)-tyrosine kinase inhibitor (TKI)–triggered apoptosis in EGFR-mutant non–small-cell lung cancer (NSCLC). A deletion in the intron two of the BIM gene results in generation of alternatively spliced isoforms that impairs their apoptotic response to TKIs, conferring the NSCLC cells intrinsic resistance to these medications. Patients with both alterations have poor clinical evolution. The current study aimed to investigate the clinical efficacy and tolerability of EGFR-TKIs plus bevacizumab (Bev) versus EGFR-TKIs alone as first-line treatment in advanced NSCLC patients with EGFR mutations and BIM deletions ( BIMdel). MATERIALS AND METHODS A retrospective analysis was conducted. BIMdel was detected using polymerase chain reaction analysis and direct sequencing of DNA. BIM protein expression was investigated by immunohistochemistry, and BIM mRNA levels by reverse transcriptase-polymerase chain reaction. Clinical characteristics, overall survival, progression-free survival (PFS), overall response rate (ORR), and treatment-related adverse events were compared between both groups. RESULTS Thirty-three patients were included; 15 received EGFR-TKIs, and 18 received EGFR-TKIs plus Bev. The median age was 63 years, with a majority of recruited female patients. All included individuals had an Eastern Cooperative Oncology Group performance score of 2 or less. The addition of Bev resulted in a significantly higher ORR (94.4% v 40%, P > .001). Median PFS was longer with the use of the combination therapy (11.12 v 7.87 months; P = .001). Median overall survival tended to be longer in the EGFR-TKIs plus Bev (30.9 v 25.4 months; P = .06) but failed to reach statistical significance. Response in terms of both partial and complete as well as overall favorably affected PFS. CONCLUSION EGFR-TKIs plus Bev conferred a significantly higher ORR and PFS in advanced NSCLC patients with EGFR mutation and BIMdel. Further prospective studies are needed to validate these findings.
Histological evaluation of acute ischemic stroke thrombi may indicate the occurrence of vessel wall injury during mechanical thrombectomy
Mereuta, Oana Madalina , Abbasi, Mehdi , Fitzgerald, Seán , Dai, Daying , Kadirvel, Ram , Almekhlafi, Mohammed , Kvamme, Peter , Gounis, Matthew J. , Patel, Biraj M. , Aghaebrahim, Amin, Sauvageau, Eric , Bhuva, Parita, Soomro, Jazba , Thacker, Ike, Copelan, Alexander , Nazari, Pouya , Cantrell, Donald R. , Mohammaden, Mahmoud , Pisani, Leonardo , Puri, Ajit S , Meves, Alexander , Larco, Jorge Arturo , Cloft, Harry J. , Kallmes, David F. , Doyle, Karen , Brinjikji, Waleed , Almekhlafi, Mohammed A , Mendes Pereira, Vitor , Jahromi, Babak S , Gounis, Matthew J , Nazari, Pouya , Al-Bayati, Alhamza , Pisani, Leonardo , Rodrigues, Gabriel Martins , Arturo Larco, Jorge L , Savastano, Luis , Doyle, Karen M , Brinjikji, Waleed , Patel, Biraj M , Fitzgerald, Seán , Dai, Daying , Madalina Mereuta, Oana , Kadirvel, Ramanathan , Hanel, Ricardó A. , Yoo, Albert J. , Layton, Kennith F. , Almandoz, Josser E Delgado , Jahromi, Babak S. , Nogueira, Raul G. , Demchuk, Andrew M. , Kayan, Yasha , Haussen, Diogo C , Al‐Bayati, Alhamza R , Entwistle, John

Mayo Clinic

Journal of NeuroInterventional Surgery | May 11, 2021 | Volume: 14 | Issue: 4 | Pages: 356-361

10.1136/neurintsurg-2021-017310 | PMID 33975922 Get It

Background Several animal studies have demonstrated that mechanical thrombectomy (MT) for acute ischemic stroke (AIS) may cause vessel wall injury (VWI). However, the histological changes in human cerebral arteries following MT are difficult to determine. Objective To investigate the occurrence of VWI during MT by histological and immunohistochemical evaluation of AIS clots. Methods As part of the multicenter STRIP registry, 277 clots from 237 patients were analyzed using Martius Scarlett Blue stain and immunohistochemistry for CD34 (endothelial cells) and smooth muscle actin (smooth muscle cells). Results MT devices used were aspiration catheters (100 cases), stentriever (101 cases), and both (36 cases). VWI was found in 33/277 clots (12%). There was no significant correlation between VWI and MT device. The degree of damage varied from grade I (mild intimal damage, 24 clots), to grade II (relevant intimal and subintimal damage, 3 clots), and III (severe injury, 6 clots). VWI clots contained significantly more erythrocytes (p=0.006*) and less platelets/other (p=0.005*) than non-VWI clots suggesting soft thrombus material. Thrombolysis correlated with a lower rate of VWI (p=0.04*). VWI cases showed a significantly higher number of passes (2 [1–4] vs 1 [1–3], p=0.028*) and poorer recanalization outcome (p=0.01*) than cases without VWI. Conclusions Histological markers of VWI were present in 12% of AIS thrombi, suggesting that VWI might be related to MT. VWI was associated with soft thrombus consistency, higher number of passes and poorer revascularization outcome. There was no significant correlation between VWI and MT device.
Abstract 15635: Myocardial Function Index Predicts Mortality in Amyloid Light Chain Cardiomyopathy
Anand, Vidhu , Ryu, Alexander J. , Anavekar, Nandan S., Chandrasekaran, Krishnaswamy , Akhiyat, Nadia , Ryu, Alexander J. , Kumar, Vinayak , Borlaug, Barry A. , AbouEzzeddine, Omar F. , Gibbons, Raymond J. , Gersh, Bernard J.

Mayo Clinic

Circulation | May 10, 2021 | Volume: 142 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.142.suppl_3.15635 Get It

Introduction: Cardiovascular disease remains the leading cause of morbidity and mortality in patients with amyloid light chain (AL) amyloidosis. Current prognostic evaluation in AL cardiomyopathy (AL-CM) largely relies upon disparate proxy measurements to assess mortality. With respect to observed myocardial volume changes between systole and diastole, we describe a single measurement derived from cardiac MRI (CMR) to assess mortality of AL-CM. Methods: A cohort of 129 consecutive patients with AL-CM undergoing CMR with amyloid protocol from the years 2001 - 1997 was reviewed. Myocardial volume change at end systole and end diastole was assessed by disc summation with CMR. The myocardial function index (MFI) was calculated by consolidating blood pool and myocardial volume measures as confluent components of myocardial function utilizing operator tracings. The association of MFI and death was assessed with adjusted hazard ratios (HR) derived by a Cox model. Results: Data at time of CMR was reviewed. The mean age was 60 ±10; 68% subjects were female. Median survival from CMR was 47 months. Mean LVEF was assessed by echocardiography to be 55% ± 12. Mean calculated MFI was 19.8% ±7. Univariate analysis suggested MFI is strongly associated with death (HR 0.004; 95%CI 0.00002-0.0838; p = 0.0003). A multivariate analysis re-demonstrated the strong predictive value of MFI when controlled for age (HR 0.006; 95%CI 0.00003 - 0.1156; p = 0.0006). Conclusion: MFI strongly correlates with mortality in AL-CM. In contrast to previously described assessments of ventricular function (extracellular volume imaging, myocardial perfusion imaging, and myocardial contraction fraction), MFI is easily derived from CMR and considers blood pool and myocardial volumes as confluent components of myocardial function. Further studies are needed to assess MFI amongst patients with varying etiologies of heart failure.
Abstract 14414: Bioprosthetic Valve Thrombosis: Different Time to Response to Warfarin in Mitral and Aortic Valves
Egbe, Alexander C. , Petrescu, Ioana, Connolly, Heidi M. , Naser, Jwan A. , Ionescu, Filip , Nkomo, Vuyisile T. , Pislaru, Cristina , Pellikka, Patricia A. , Pislaru, Sorin V.

Mayo Clinic

Circulation | May 10, 2021 | Volume: 142 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.142.suppl_3.14414 Get It

Background: Warfarin is known to be effective in the treatment of bioprosthetic valve thrombosis (BPVT). However, the time-course of response to anticoagulation has not been fully characterized. Hypothesis: We hypothesized that response to warfarin can differ depending on valve position. Methods: We retrospectively identified 45 patients with BPVT diagnosis between 2002 and 2019 that involved either the mitral (MV) or the aortic valve (AV) prostheses, all with eventual echocardiographic resolution with warfarin. BPVT involved AV in 26 (57.8%) patients and MV in 19 (42.2%). Mean gradients (MGs) were tracked starting from BPVT diagnosis until recovery, which was defined as MGs decreasing to initial post-implantation MGs, to 50% below MGs at BPVT diagnosis, or to < 20 mmHg in AV and < 5 mmHg in MV. Kaplan Meier analysis was used to compare recovery time between MV and AV. Duration is reported relative to the time of BPVT diagnosis. Results: Recovery was faster in MV than in AV patients treated with warfarin, with median time of 3.8 months in the AV and 1.8 months in the MV group, p < 0.001 (Figure 1). At 1 month follow up, 15.4% recovered in AV group and 21.1% in MV, p = 0.605. At 3 months, 38.5% recovered in the AV and 78.9% in the MV, p = 0.009. At 6 months, 57.7% of AV group recovered while 100% recovered in the MV group, p = 0.001. The longest time for recovery was 30 months in 1 AV patient. Conclusion: Recovery using warfarin tended to be faster in BPVT involving the MV compared with the AV. In our study, all patients with MV BPVT recovered by 6 months, while this only happened in half the patients with AV BPVT. This suggests that a longer duration of warfarin trial may be needed in the case of AV disease. This might also suggest that the pathogenesis may differ between the two valves.
Abstract 13781: Recurrence of Papillary Fibroelastoma
Sorour, Ahmed A. , Kurmann, Reto , El‐Am, Edward , Bois, Melanie C. , Maleszewski, Joseph J. , Klarich, Kyle W. , Scott, Christopher G. , Lee, Alexander , Dearani, Joseph A.

Mayo Clinic

Circulation | May 10, 2021 | Volume: 142 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.142.suppl_3.13781 Get It

Background: Papillary fibroelastoma (PFE) is the most common benign cardiac tumor. Because PFEs have the potential to embolize, they typically are surgically excised. Prior studies have suggested that postoperative recurrence of PFE is rare or does not occur. Objectives: To determine the rate at which PFEs recurred after surgical removal and to identify any risk factors associated with recurrence. Methods: Patients with pathologically proven PFE were retrospectively identified from a single center. Patients were included in the study if they had an echocardiographic examination at least 1 year after surgery. Echocardiographic images obtained intraoperatively (after excision) and at dismissal were compared with those of the most recent examination to assess the possibility of PFE recurrence. Results: Ninety eight patients were identified. The mean (SD) duration of follow-up was 5.4 (3.7) years (range, 1-17 years). Twelve patients (12.2%) had echocardiographically proven PFE recurrence. Three patients had the recurrent lesion surgically re-excised, and pathologic analysis showed that 2 were recurrent PFEs and 1 was a Lambl excrescence. Clinical presentation of stroke or TIA was more common for the recurrence patients (for the first PFE) than for the nonrecurrence patients (83% vs 26%; P <.001). Conclusions: Contrary to published data, PFEs do recur after surgical excision. This emphasizes the importance of postoperative follow-up with transesophageal echocardiography for identifying recurrent masses. Table. Characteristics of Patients With Recurrent PFE Abbreviations: AV, aortic valve; LA, left atrium; LE, Lambl excrescence; LVOT, left ventricular outflow tract; MV, mitral valve; PV, pulmonary valve; RA, right atrium; RC, right cusp; TV, tricuspid valve. a Corresponds to the same location. b Corresponds to a different location .
Abstract 12588: Characteristics and Survival After Transcatheter Aortic Valve Replacement in Immunocompromised Patients: A Cohort Study
Ball, Colleen, Gharacholou, S. Michael , Pollak, Peter , Parikh, Pragnesh , Landolfo, Carolyn, Ali, Mays T. , Landolfo, Kevin , Ghannam, Alexander D.

Mayo Clinic

Circulation | May 10, 2021 | Volume: 142 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.142.suppl_3.12588 Get It

Background: Immunocompromised (IC) patients are at greater risk from cardiac surgery. Transcatheter aortic valve replacement (TAVR) may be more preferable for treating severe aortic stenosis (AS), though data regarding outcomes of IC patients are limited. Methods: We reviewed TAVR procedures performed at our institution from 1/2015-12/2019.We defined IC as either active malignancy receiving oncologic treatment or post organ transplant on immunosuppression, HIV, chronic steroid use (>5mg/day), or autoimmune disorder. Survival probability was estimated using the Kaplan-Meier (KM) method. Cox regression was used to evaluate the association of IC with survival. Results: Of 173 patients who underwent TAVR, 56 (32%) were IC: 30 (54%) had active malignancy undergoing active treatment, 19 (34%) were IC without malignancy, and 7 (13%) had both. Among the 19 IC patients without malignancy, 4 were post organ transplant, 3 were taking chronic steroids, 2 had autoimmune disorder, 1 had HIV, and 10 had ≥2 combination of the above. IC patients, as compared to non-IC patients, had similar baseline demographics and STS risk score (median 4.3 vs. 4.4), respectively. There were 37 deaths (16 IC and 21 non-IC) over a median follow up of 1.4 years (IQR 1.0-2.0 years). 1-year survival after TAVR was 84.5% for IC patients and 89.0% for non-IC patients (log rank p = 0.51). After adjusting for age and sex, an association between IC and survival was observed but not found to be statistically significant (adjusted HR, 1.55; 95% CI, 0.80-3.00). Conclusions: IC patients undergoing TAVR have similar baseline characteristics as non-IC patients with a trend towards worse survival. Longer term follow-up may help clarify the impact of IC status on survival after TAVR.
Visual Outcomes and Complications After Lensectomy for Traumatic Cataract in Children
Enyedi, Laura B. , Jones, Sarah K., Hug, Denise, Stahl, Erin D., Dent, Rebecca J., Yen, Kimberly G., Kong, Lingkun , Wang, Serena , Gallerson, Bryan K., Lambert, Scott R. , Hutchinson, Amy K., Brower, Judy, Ruark, Scott T., Rahmani, Bahram , Kurup, Sudhi P. , Mets-Halgrimson, Rebecca, Yoon, Hawke , Hamidullah, Aaliyah, Anderson, Jill S., Holleschau, Ann M., Superstein, Rosanne , Bélanger, Caroline, Fallaha, Nicole, Hamel, Patrick , Thibeault, Maryse, Tamkins, Susanna M. , Kraus, Courtney L. , Park, Hee-Jung S., Trumler, Anya A., Liu, Xiaonong, Astle, William F., Sanders, Emi , McOwen, Diana C., Yang, Michael B. , Bowman, Corey S., Galvin, Jennifer, Therriault, Margaret, Haider, Kathryn M. , Smith, Heather , Whitaker, Michele E., Örge, Faruk , Grigorian, A. Paula, Baird, Alicia M., Strominger, Mitchell B. , Klein, Shelley, Campomanes, Alejandra de Alba, Kemmer, Jacquelyn D., Neiman, Alexandra E., Mendoza, Myra N., Frohwein, Jill J., Bremer, Don L., Cassady, Cybil, Golden, Richard P., Jordan, Catherine O., Oravec, Sara A., Yanovitch, Tammy L. , Lunsford, Keven, Whitehead, George F., Nye, Christina, Shea, Caroline, Stillman, SueAnn M., Iderstine, Stephen C. Van, Young, Marielle P. , Robertson, Elisa, Cruz, Oscar A., Ghadban, Rafif, Govreau, Dawn, Longmuir, Susannah Q. , Shan, Xiaoyan, Taylor, Kate , Powell, Christine, Hammond, Benjamin P., Gearinger, Matthew D., Czubinski, Andrea, Salvin, Jonathan, Fisher, Alicia, Lee, Katherine A., Brooks, Daniel , Schweinler, Bonita R., Sala, Nicholas A., Sala, Allyson M., Summers, Allison I. , Karr, Daniel J. , Wilson, Lorri B., Rauch, Paula K., O’Hara, Mary, Gandhi, Nandini, Hashmi, Tania, Colburn, Jeffrey, Dittman, Eileen, Whitfill, Charles R., Wheeler, Amy M., McCourt, Emily A. , Singh, Jasleen , Welnick, Nanastasia, Azar, Nathalie F., Baker, Joseph, Droste, Patrick J. , Peters, Robert J., Hilbrands, Jan, Pineles, Stacy L., Bernardo, Marianne J., Peterson, Edward, Peterson, Charla H., Kumar, Kartik , Melese, Ephrem, Lingua, Robert W., Grijalva, Jeff, Crouch, Earl R., Ventura, Gaylord, Anninger, William, Benson, Shawn L., Karp, Karen A. , Smith, Jordana M., Brickman-Kelleher, Jill, Ticho, Benjamin H., Khammar, Alexander J., Clausius, Deborah A., Guo, Suquin, Chamberlain, Carolyn, Schloff, Susan, Madigan, William P., Burkman, Donna, Ramsey, Jean E., McConnell, Kate H. , Friedman, Ilana, Rosado, José , Sauberan, Donald P., Hemberger, Jody C., Davis, Patricia L., Rudaitis, Indre, Lowery, Robert S., Cupit, Shawn, Mohney, Brian G., Wernimont, Suzanne M., Neilsen, Rebecca A., Herlihy, Erin P. , Baran, Francine, Gladstone, Amy, Smith, Justin , Mellott, Mei, Kieser, Troy, Erzurum, S. Ayse , Colon, Beth, Shah, Birva, Quebbemann, Micaela, Austin, Darrell S., Boyle, Nicole M., Conner, Courtney L., Chandler, Danielle L. , Donahue, Quayleen, Fimbel, Brooke P., Hardt, Graham M., Hoepner, James E., Kaplon, Joseph D., Lazar, Elizabeth L., Melia, Michele , Ortiz, Gillaine, Rojas, Diana E., Shah, Jennifer A., Everett, Donald F., Diener‐West, Marie , Baker, John D., Davis, Barry R. , Phelps, Dale L. , Poff, Stephen W., Tychsen, Lawrence , Bradfield, Yasmin S., Foster, Nicole C. , Plager, David A. , Silver, Jayne L., Weise, Katherine K., Verderber, Lisa C. , Bothun, Erick D. , Repka, Michael X. , Dean, Trevano W., Gray, Michael E. , Lenhart, Phoebe D. , Li, Zhuokai , Morrison, David G., Wallace, David K. , Kraker, Raymond T. , Holmes, Jonathan M. , Freedman, Sharon F. , Prakalapakorn, Sasapin Grace , Ranaivo, Hantamalala Ralay , Areaux, Raymond G. , Chang, Ta Chen , Traboulsi, Elias I. , Ghasia, Fatema F. , Chen, Vicki, Campomanes, Alejandra G. de Alba , Rogers, David L. , LaRoche, G. Robert, Larson, Scott A. , Clarke, Michael W. , Hendricks, Dorothy H. , Jin, Jing , Brooks, Daniel, Rauch, Paula K., Baker, Joseph, Peterson, Edward, Suh, Donny Won , Christiansen, Stephen P. , Beck, Roy W. , Wu, Rui , Saunders, Richard Anthony , Salchow, Daniel J. , Birch, Eileen E. , Manny, Ruth E. , Cotter, Susan A. , Holmes, Jonathan M.

Mayo Clinic

JAMA Ophthalmology | May 7, 2021 | Volume: 139 | Issue: 6 | Pages: 647

10.1001/jamaophthalmol.2021.0980 | PMID 33956055 Get It